MD3653F2 - Forme polimorfe de rifaximina, procedee deobtinere a lor si utilizarea acestora in calitatede antibiotic - Google Patents

Forme polimorfe de rifaximina, procedee deobtinere a lor si utilizarea acestora in calitatede antibiotic Download PDF

Info

Publication number
MD3653F2
MD3653F2 MDA20060080A MD20060080A MD3653F2 MD 3653 F2 MD3653 F2 MD 3653F2 MD A20060080 A MDA20060080 A MD A20060080A MD 20060080 A MD20060080 A MD 20060080A MD 3653 F2 MD3653 F2 MD 3653F2
Authority
MD
Moldova
Prior art keywords
rifaximin
water content
2theta
ray powder
polymorphic forms
Prior art date
Application number
MDA20060080A
Other languages
English (en)
Other versions
MD3653G8 (ro
MD20060080A (ro
Inventor
Giuseppe C. Viscomi
Manuela Campana
Dario Braga
Donatella Confortini
Vincenzo Cannata
Paolo Righi
Gofftredo Rosini
Original Assignee
Alfa Wassermann S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33187382&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MD3653(F2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alfa Wassermann S.P.A. filed Critical Alfa Wassermann S.P.A.
Publication of MD20060080A publication Critical patent/MD20060080A/ro
Publication of MD3653F2 publication Critical patent/MD3653F2/ro
Publication of MD3653G8 publication Critical patent/MD3653G8/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • H—ELECTRICITY
    • H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05B—ELECTRIC HEATING; ELECTRIC LIGHT SOURCES NOT OTHERWISE PROVIDED FOR; CIRCUIT ARRANGEMENTS FOR ELECTRIC LIGHT SOURCES, IN GENERAL
    • H05B6/00—Heating by electric, magnetic or electromagnetic fields
    • H05B6/02—Induction heating
    • H05B6/10—Induction heating apparatus, other than furnaces, for specific applications
    • H05B6/12—Cooking devices
    • H05B6/1209—Cooking devices induction cooking plates or the like and devices to be used in combination with them
    • H05B6/1236—Cooking devices induction cooking plates or the like and devices to be used in combination with them adapted to induce current in a coil to supply power to a device and electrical heating devices powered in this way
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • H—ELECTRICITY
    • H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05B—ELECTRIC HEATING; ELECTRIC LIGHT SOURCES NOT OTHERWISE PROVIDED FOR; CIRCUIT ARRANGEMENTS FOR ELECTRIC LIGHT SOURCES, IN GENERAL
    • H05B6/00—Heating by electric, magnetic or electromagnetic fields
    • H05B6/02—Induction heating
    • H05B6/10—Induction heating apparatus, other than furnaces, for specific applications
    • H05B6/12—Cooking devices
    • H05B6/1209—Cooking devices induction cooking plates or the like and devices to be used in combination with them
    • H05B6/1245—Cooking devices induction cooking plates or the like and devices to be used in combination with them with special coil arrangements
    • H05B6/1263—Cooking devices induction cooking plates or the like and devices to be used in combination with them with special coil arrangements using coil cooling arrangements

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Electromagnetism (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)

Abstract

Inventia se refera la forme polimorfe de rifaximina, si anume la formele Alpha, Beta, Gamma.Forma polimorfa Alpha de rifaximina are un continut de apa mai mic de 4,5% si o difractograma a pulberii curaze X manifestand varfuri la valorile unghiurilor de difractie 2Theta 6,6°; 7,4o; 7,9°; 8,8o; 10,5°; 11,1o; 11,8°; 12,9°; 17,6°; 18,5°; 19,7°; 21,0°; 21,4°; 22,1°.Forma polimorfa Beta de rifaximina are un continut de apa mai mare de 4,5% si o difractograma a pulberii cu raze X manifestand varfuri la valorile unghiurilor de difractie 2Theta 5,4°; 6,4°; 7,0°; 7,8°; 9,0°; 10,4°; 13,1°; 14,4°; 17,1°; 17,9°; 18,3°; 20,9°.Forma polimorfa Gamma de rifaximina are un continut de apa intre 1,0% si 2,0% si o difractograma a pulberii cu raze X manifestand, in general, un profil amorf si cateva varfuri semnificative la valorile unghiurilor de difractie 2Theta 5,0°; 7,1°; 8,4°.Inventia se refera de asemenea la procedee de obtinere a lor, la care prin incalzire se dilueaza rifaximina bruta in alcool etilic si se initiaza cristalizarea produsului prinadaugarea apei la o temperatura anumita, pe parcursul unui anumit interval de timp, dupa care se realizeaza uscarea sub control, pana cand produsul finit ajunge la un anumit continut de apa.Formele polimorfe obtinute de rifaximina se utilizeaza in calitate de preparate medicamentoase cu actiune antibiotica pentru administrare orala si locala.
MDA20060080A 2003-11-07 2004-11-04 Forme polimorfe de rifaximină, procedee de obţinere a lor şi utilizarea acestora în calitate de antibiotic MD3653G8 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT002144A ITMI20032144A1 (it) 2003-11-07 2003-11-07 Forme polimorfe di rifaximina, processi per ottenerle e
PCT/EP2004/012490 WO2005044823A2 (en) 2003-11-07 2004-11-04 Polymorphous forms of rifaximin as antibiotics

Publications (3)

Publication Number Publication Date
MD20060080A MD20060080A (ro) 2006-11-30
MD3653F2 true MD3653F2 (ro) 2008-07-31
MD3653G8 MD3653G8 (ro) 2016-08-31

Family

ID=33187382

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20060080A MD3653G8 (ro) 2003-11-07 2004-11-04 Forme polimorfe de rifaximină, procedee de obţinere a lor şi utilizarea acestora în calitate de antibiotic

Country Status (37)

Country Link
US (5) US7045620B2 (ro)
EP (6) EP1676848B1 (ro)
JP (5) JP2005139161A (ro)
KR (4) KR20050043589A (ro)
CN (4) CN1613858A (ro)
AR (3) AR043547A1 (ro)
AT (3) ATE361927T1 (ro)
AU (2) AU2004200964A1 (ro)
BR (2) BRPI0402382A (ro)
CA (2) CA2460384A1 (ro)
CL (1) CL2004000498A1 (ro)
CO (1) CO5560083A1 (ro)
CY (3) CY1108017T1 (ro)
DE (4) DE602004019298D1 (ro)
DK (3) DK1557421T3 (ro)
ES (3) ES2320161T3 (ro)
HR (2) HRP20040265A2 (ro)
IL (2) IL160798A0 (ro)
IT (1) ITMI20032144A1 (ro)
JO (1) JO2470B1 (ro)
MA (1) MA27069A1 (ro)
MD (1) MD3653G8 (ro)
ME (1) ME00424B (ro)
MX (2) MXPA04002353A (ro)
NO (1) NO334950B1 (ro)
NZ (1) NZ531622A (ro)
PL (3) PL1557421T3 (ro)
PT (3) PT1676847E (ro)
RS (4) RS54571B1 (ro)
RU (1) RU2270200C2 (ro)
SI (3) SI1676848T1 (ro)
TN (2) TNSN04044A1 (ro)
TW (1) TWI285107B (ro)
UA (1) UA86384C2 (ro)
WO (1) WO2005044823A2 (ro)
YU (1) YU24804A (ro)
ZA (1) ZA200401948B (ro)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD4081G2 (ro) * 2005-03-03 2011-07-31 Alfa Wassermann S.P.A. Forme polimorfe de rifaximină, procedee de obţinere şi utilizare a acestora în calitate de preparate medicamentoase cu activitate antibiotică

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US20080262024A1 (en) * 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Rifaximin compositions and method of use
US7902206B2 (en) * 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US7923553B2 (en) * 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
US7906542B2 (en) * 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
ITBO20050123A1 (it) * 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
SI2054066T1 (sl) 2006-08-02 2015-08-31 Salix Pharmaceuticals, Inc. Postopki za zdravljenje radiacijskega enteritisa
ITMI20061692A1 (it) 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
US8633234B2 (en) * 2006-09-22 2014-01-21 Cipla Limited Rifaximin
US20080161337A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Chronic Prostatitis
US20080159987A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Restless Legs Syndrome
ITMI20071241A1 (it) * 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
AU2016203925B2 (en) * 2007-07-06 2016-10-20 Lupin Limited Pharmaceutical compositions of rifaximin
PL2011486T5 (pl) * 2007-07-06 2016-09-30 Lupin Ltd Farmaceutyczne kompozycje rifaksyminy
AU2008273699A1 (en) * 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions of rifaximin
US7709634B2 (en) * 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
CN102015725B (zh) * 2008-02-25 2014-10-22 萨利克斯药品有限公司 利福昔明的多种形式及其用途
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
EP3563850A1 (en) 2008-02-26 2019-11-06 Salix Pharmaceuticals, Ltd. Methods for treating bowel diseases
US11779571B2 (en) 2008-02-26 2023-10-10 Salix Pharmaceuticals, Inc. Methods for treating irritable bowel syndrome (IBS)
HRP20140939T1 (hr) 2008-05-07 2014-11-21 Salix Pharmaceuticals, Ltd. Davanje preparata za äśišä†enje crijeva i antibiotika za lijeäśenje bolesti crijeva
AU2009297562B2 (en) 2008-09-26 2015-04-23 Alfasigma S.P.A. Agent for preventing and/or treating functional gastrointestinal disorder
ES2972135T3 (es) 2008-10-02 2024-06-11 Salix Pharmaceuticals Inc Tratamiento de encefalopatía hepática usando rifaximina
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
US20100317681A1 (en) * 2009-06-15 2010-12-16 Salix Pharmaceuticals, Ltd. Modulation of systemic exposure to rifaximin
US12285414B2 (en) 2008-10-02 2025-04-29 Salix Pharmaceuticals, Inc. Methods of treating hepatic encephalopathy
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
CA2745980C (en) 2008-12-10 2017-10-31 Cipla Limited Rifaximin complexes
IT1397617B1 (it) * 2009-04-20 2013-01-18 Alfa Wassermann Spa Nuovi derivati della rifamicina
NZ596851A (en) * 2009-06-02 2013-10-25 Salix Pharmaceuticals Ltd Methods of treating hepatic encephalopathy
KR20120062897A (ko) 2009-09-13 2012-06-14 샐릭스 파마슈티컬스 리미티드 과민성 장 증후군(ｉｂｓ)의 치료방법
UA110199C2 (xx) * 2009-10-27 2015-12-10 Lupin Ltd Тверда дисперсія рифаксиміну
WO2011061748A1 (en) * 2009-11-19 2011-05-26 Strides Arcolab Limited Rifaximin premix
MX2012005883A (es) 2009-11-23 2012-10-09 Cipla Ltd Composicion topica en espuma.
EP2401282B2 (en) † 2009-12-28 2017-01-04 Silvio Massimo Lavagna Method for the production of amorphous rifaximin
AU2011218129A1 (en) 2010-02-18 2012-08-23 Board Of Regents Of The University Of Texas System Methods for treating infection
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
AU2011261283B2 (en) * 2010-06-03 2015-05-14 Salix Pharmaceuticals, Ltd. New forms of rifaximin and uses thereof
US8883795B2 (en) * 2010-06-16 2014-11-11 Apotex Pharmachem Inc. Polymorphic forms of Rifaximin
GEAP202112996A (en) * 2010-07-12 2021-09-10 Salix Pharmaceuticals Ltd Us Formulations of rifaximin and uses thereof
WO2012035544A2 (en) 2010-09-13 2012-03-22 Sequent Scientific Ltd. A novel polymorphic form of rifaximin and process for its preparation
IT1403847B1 (it) * 2010-09-22 2013-11-08 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina e loro uso.
WO2012060675A1 (es) * 2010-11-05 2012-05-10 Interquim, S.A. De C.V. Proceso para la preparación de rifaximina amorfa
WO2012076832A1 (en) * 2010-12-09 2012-06-14 Cipla Limited Suppositories comprising rifaximin
EP2672970B1 (en) 2011-02-11 2018-08-01 Salix Pharmaceuticals, Ltd. Forms of rifaximin and uses thereof
WO2012150561A1 (en) 2011-05-02 2012-11-08 Ranbaxy Laboratories Limited Rifaximin dimethylformamide solvate
ITMI20110890A1 (it) * 2011-05-19 2012-11-20 A M S A Anonima Materie Sint & Affini S P A Polimorfo di rifaximina e processo per la sua preparazione
WO2012155981A1 (en) 2011-05-19 2012-11-22 Friulchem Spa New process for the synthesis of rifaximin and a new pseudo-crystalline form of rifaximin obtained thereby
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
US20130184302A1 (en) 2011-11-02 2013-07-18 Enoch Bortey Methods for treating irritable bowel syndrome (ibs) and infections
JP2013184902A (ja) * 2012-03-06 2013-09-19 Aska Pharmaceutical Co Ltd リファキシミン含有結晶
US9359374B2 (en) 2012-06-13 2016-06-07 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
WO2014091432A1 (en) 2012-12-12 2014-06-19 Ranbaxy Laboratories Limited Pharmaceutical compositions of rifaximin
EP2971062A2 (en) 2013-03-15 2016-01-20 ALFA WASSERMANN S.p.A. Method for diagnosing vaginal infections
CA2897758A1 (en) 2013-03-15 2014-09-18 Alfa Wassermann S.P.A. Rifaximin for use in the treating of vaginal infections
US20140308350A1 (en) 2013-04-12 2014-10-16 Alfa Wassermann S.P.A. Nsaid administration and related compositions, methods and systems
US9018225B1 (en) 2013-07-26 2015-04-28 Novel Laboratories Rifaximin crystalline forms and methods of preparation thereof
ES2621557T3 (es) * 2014-03-31 2017-07-04 Euticals S.P.A. Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas
US9765088B2 (en) 2014-04-19 2017-09-19 Granules India Limited Process for the preparation of rifamycin derivatives
JP6693946B2 (ja) 2014-05-04 2020-05-13 サリックス ファーマスーティカルズ，インコーポレーテッド Ｉｂｓ微生物叢及びその使用
US9938298B2 (en) 2014-05-12 2018-04-10 Alfa Wassermann S.P.A. Solvated crystal form of rifaximin, production, compositions and uses thereof
KR102318025B1 (ko) * 2014-06-30 2021-10-27 샐릭스 파마슈티컬스 인코포레이티드 과민성 대장 증후군(ibs)의 재치료 방법
CN104083324B (zh) * 2014-07-10 2017-05-10 青岛动保国家工程技术研究中心有限公司 一种利福昔明的兽用悬乳剂及其制备方法和应用
EP2982764A1 (en) 2014-08-05 2016-02-10 ALFA WASSERMANN S.p.A. Identification of vaginal bacteria
CN104274391B (zh) * 2014-10-08 2017-02-01 哈尔滨坤盟医药科技有限公司 一种含利福昔明的药物制剂
WO2017021975A1 (en) * 2015-08-06 2017-02-09 Msn Laboratories Private Limited Process for the preparation of crystalline forms of rifaximin
PL3373914T5 (pl) 2016-03-24 2022-10-17 Sandoz Ag Trwała przy przechowywaniu kompozycja zawierająca rifaksyminę alfa
ES2700423T3 (es) 2016-03-24 2019-02-15 Sandoz Ag Composición farmacéutica que contiene rifaximina alfa y delta
US9988398B2 (en) * 2016-06-07 2018-06-05 Cadila Healthcare Limited Crystalline form of rifaximin and process for its preparation
CA3038312A1 (en) 2016-09-30 2018-04-05 Salix Pharmaceuticals, Inc. Solid dispersion forms of rifaximin
CN106632396B (zh) * 2017-01-06 2019-01-11 成都樵枫科技发展有限公司 γ晶型利福昔明的制备方法和用途
WO2018197538A1 (en) 2017-04-26 2018-11-01 Sandoz Ag Oral dosage form comprising rifaximin in form beta
WO2019003076A1 (en) 2017-06-26 2019-01-03 Biofer S.P.A. PYRIDO-IMIDAZO-RIFAMYCIN DERIVATIVES AS ANTIBACTERIAL AGENT
EP3902528A1 (en) * 2018-12-19 2021-11-03 Friulchem SpA Process for the manufacture of a tablet of rifaximin and tablet of rifaximin
CA3142214A1 (en) 2019-06-03 2020-12-10 Bausch Health Ireland Limited Use of methylnaltrexone and rifaximin for treatment of increased gut permeability or associated disorders
CN114401721A (zh) 2019-09-24 2022-04-26 博士医疗爱尔兰有限公司 利福昔明液体制剂
US20230116647A1 (en) 2020-03-24 2023-04-13 Bausch Health Ireland Limited Methods of treating covid-19 with rifaximin
WO2021229480A1 (en) * 2020-05-15 2021-11-18 Atra Pharmaceuticals Limited Polymorph of rifaximin, process for the preparation thereof and pharmaceutical composition containing rifaximin
AU2021298178A1 (en) 2020-06-26 2023-02-02 Bausch Health Ireland Limited Targeted release rifaximin compositions
WO2022090490A1 (en) 2020-10-29 2022-05-05 Bausch Health Ireland Limited Rifaximin liquid formulations for use in the treatment of sickle cell disease

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4241785A (en) * 1978-07-24 1980-12-30 Peerless Of America, Inc. Heat exchangers and method of making same
IT1154655B (it) * 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
IT1199374B (it) * 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
CA1215976A (en) 1984-05-15 1986-12-30 Vincenzo Cannata New process for the synthesis of imidazo rifamycins
IT1199413B (it) 1984-09-26 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
GB8816620D0 (en) * 1988-07-13 1988-08-17 Lepetit Spa Rifapentine hydrohalides
ES2075454T3 (es) * 1990-06-29 1995-10-01 Lepetit Spa Forma cristalina pura de rifapentina.
CZ20022332A3 (cs) * 2000-01-07 2003-01-15 Transform Pharmaceuticals, Inc. Sestava vzorků
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
EP1330427A1 (en) * 2000-10-31 2003-07-30 Ciba SC Holding AG Crystalline forms of venlafaxine hydrochloride
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US20050262269A1 (en) 2004-05-20 2005-11-24 Pike Jimmy D System and method for information handling system PCI express advanced switching
PL1698630T3 (pl) 2005-03-03 2014-12-31 Alfasigma Spa Nowe postacie polimorficzne rifaksyminy,sposoby ich wytwarzania i ich zastosowanie w preparatach leczniczych
US8633234B2 (en) 2006-09-22 2014-01-21 Cipla Limited Rifaximin
WO2008115572A1 (en) 2007-03-21 2008-09-25 Theraquest Biosciences, Inc. Methods and compositions of nsaids
ITMI20071241A1 (it) 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
AU2008273699A1 (en) 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions of rifaximin
PL2011486T5 (pl) 2007-07-06 2016-09-30 Lupin Ltd Farmaceutyczne kompozycje rifaksyminy
US7709634B2 (en) 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
JP2011500552A (ja) 2007-10-10 2011-01-06 ルピン・リミテッド 胃腸障害を処置するための医薬用組み合わせおよび組成物
CN102015725B (zh) 2008-02-25 2014-10-22 萨利克斯药品有限公司 利福昔明的多种形式及其用途

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD4081G2 (ro) * 2005-03-03 2011-07-31 Alfa Wassermann S.P.A. Forme polimorfe de rifaximină, procedee de obţinere şi utilizare a acestora în calitate de preparate medicamentoase cu activitate antibiotică

Also Published As

Publication number Publication date
US8173801B2 (en) 2012-05-08
AU2004287601A1 (en) 2005-05-19
TNSN04044A1 (en) 2006-06-01
MD3653G8 (ro) 2016-08-31
MA27069A1 (fr) 2004-12-20
TW200515913A (en) 2005-05-16
SI1676847T1 (sl) 2009-06-30
BRPI0407149A (pt) 2006-02-07
PL1676847T3 (pl) 2009-07-31
RU2270200C2 (ru) 2006-02-20
RS20150291A1 (sr) 2015-10-30
ITMI20032144A1 (it) 2005-05-08
WO2005044823A3 (en) 2005-10-27
DE602004006367T2 (de) 2007-09-06
CN1886408B (zh) 2010-06-09
US20050101598A1 (en) 2005-05-12
RS20150292A1 (sr) 2015-10-30
EP1676847A1 (en) 2006-07-05
EP1676848A1 (en) 2006-07-05
CA2538546A1 (en) 2005-05-19
US20050272754A1 (en) 2005-12-08
CN1613858A (zh) 2005-05-11
CL2004000498A1 (es) 2005-03-11
EP2210893A1 (en) 2010-07-28
RS54569B1 (sr) 2016-06-30
EP1557421A1 (en) 2005-07-27
ES2244364T3 (es) 2007-12-01
KR100855084B1 (ko) 2008-08-29
ATE361927T1 (de) 2007-06-15
US8404704B2 (en) 2013-03-26
NO334950B1 (no) 2014-08-04
JO2470B1 (en) 2009-01-20
UA86384C2 (uk) 2009-04-27
TWI285107B (en) 2007-08-11
IL174271A0 (en) 2006-08-01
HRP20060093B1 (hr) 2015-12-18
ES2320160T4 (es) 2011-03-09
TNSN06069A1 (en) 2007-10-03
KR100883216B1 (ko) 2009-02-13
CN101260115A (zh) 2008-09-10
PT1557421E (pt) 2007-07-31
PL1676848T3 (pl) 2009-07-31
DK1676848T3 (da) 2009-05-11
AU2004287601B2 (en) 2009-02-26
SI1557421T1 (sl) 2007-08-31
JP2014177500A (ja) 2014-09-25
CO5560083A1 (es) 2005-09-30
ZA200401948B (en) 2004-04-29
AR081991A2 (es) 2012-10-31
US20110160449A1 (en) 2011-06-30
AU2004200964A1 (en) 2005-05-26
WO2005044823A2 (en) 2005-05-19
NO20061110L (no) 2006-04-19
US7045620B2 (en) 2006-05-16
DE602004006367C5 (de) 2019-04-04
RS20060168A (sr) 2008-09-29
KR20060110737A (ko) 2006-10-25
DK1676847T3 (da) 2009-05-11
AR043547A1 (es) 2005-08-03
CA2460384A1 (en) 2005-05-07
JP2011057698A (ja) 2011-03-24
ES2244364T1 (es) 2005-12-16
US20080132530A1 (en) 2008-06-05
PT1676847E (pt) 2009-04-09
JP5199576B2 (ja) 2013-05-15
HK1073657A1 (en) 2005-10-14
US7915275B2 (en) 2011-03-29
KR20070113326A (ko) 2007-11-28
JP2007509904A (ja) 2007-04-19
EP1676848B1 (en) 2009-01-28
HK1092150A1 (en) 2007-02-02
IL174271A (en) 2010-12-30
ATE421965T1 (de) 2009-02-15
MXPA06002644A (es) 2006-06-06
DE04005541T1 (de) 2005-12-29
DE602004019298D1 (de) 2009-03-19
ES2320161T3 (es) 2009-05-19
EP1557421B1 (en) 2007-05-09
CY1108964T1 (el) 2014-07-02
DK1557421T3 (da) 2007-09-17
AU2004287601B8 (en) 2009-03-05
CY1108017T1 (el) 2013-09-04
SI1676848T1 (sl) 2009-06-30
JP5635376B2 (ja) 2014-12-03
HK1092151A1 (en) 2007-02-02
EP2208730A1 (en) 2010-07-21
ES2320160T3 (es) 2009-05-19
HRP20040265A2 (en) 2004-12-31
IL160798A0 (en) 2004-08-31
RS54571B1 (sr) 2016-06-30
MD20060080A (ro) 2006-11-30
BRPI0407149A8 (pt) 2019-01-15
CN101260115B (zh) 2011-11-23
MXPA04002353A (es) 2005-05-11
PT1676848E (pt) 2009-04-09
DE602004006367D1 (de) 2007-06-21
KR100867751B1 (ko) 2008-11-10
EP1676847B1 (en) 2009-01-28
US20120059023A1 (en) 2012-03-08
JP2011046738A (ja) 2011-03-10
ATE421966T1 (de) 2009-02-15
CN101260114A (zh) 2008-09-10
EP1682556A2 (en) 2006-07-26
CA2538546C (en) 2011-04-19
CN101260114B (zh) 2012-11-28
JP2005139161A (ja) 2005-06-02
KR20050043589A (ko) 2005-05-11
BRPI0402382A (pt) 2005-06-28
PL1557421T3 (pl) 2007-08-31
CN1886408A (zh) 2006-12-27
YU24804A (sh) 2006-08-17
AR081992A2 (es) 2012-10-31
HRP20060093A2 (en) 2006-05-31
KR20070113327A (ko) 2007-11-28
RU2004108953A (ru) 2005-10-27
CY1108909T1 (el) 2014-07-02
RS54568B1 (sr) 2016-06-30
DE602004019296D1 (de) 2009-03-19
NZ531622A (en) 2004-10-29
ME00424B (me) 2011-10-10

Similar Documents

Publication Publication Date Title
MD3653F2 (ro) Forme polimorfe de rifaximina, procedee deobtinere a lor si utilizarea acestora in calitatede antibiotic
HRP20070433B1 (hr) Novi polimorfni oblici rifaksimina, postupci njihove pripreme i njihova medicinska upotreba
LV12735A (en) Manufacture and pharmaceutical compositions thereof
NO20043038L (no) Polymorfe former av klopidogrel-hydrogensulfat
HUE037560T2 (hu) Glikolipid-származékok, eljárás elõállításukra, szintézis-köztitermékeik, és eljárás a köztitermékek elõállítására
NZ585880A (en) Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
NZ596872A (en) Improved method for synthesizing pirfenidone
CA2600203A1 (en) New salt and polymorphs of a dpp-iv inhibitor
HRP20160520T1 (hr) ČVRSTI OBLICI KOJI SADRŽE N-(5-TERC-BUTIL-IZOKSAZOL-3-IL)-N'-{4-[7-(2-MORFOLIN-4-IL-ETOKSI)IMIDAZO[2,1-b]BENZOTIAZOL-2-IL]FENIL}UREJU, NJIHOVI SASTAVI I NJIHOVE UPORABE
GEP20094577B (en) New crystalline form iv of agomelatine, a process for its preparation and pharmaceutical compositions containing it
HUP0302336A2 (hu) 5-Klór-3-(4-metánszulfonilfenil)-6'-metil-[2,3']bipiridinil tiszta formában és eljárás előállítására
CN106588911A (zh) 一种抗变形链球菌的新型噻唑类化合物xqh‑3‑6及其应用
GEP20094576B (en) New cyrstalline form iii of agomelatine, a process for its preparation and pharmaceutical compositions containing it
MX2010007294A (es) Dutasterida solida y cristalina y procesos para la preparacion de la misma.
TW200504003A (en) Method for producing ditrimethylolpropane
NO20052998D0 (no) Alfa krystallinsk form av strontiumranelat, fremgangsmate for dens fremstilling og farmasoytiske sammensetninger inneholdende den.
WO2005044824A3 (en) Processes for the preparation of highly pure 3-(2-substituted vinyl) cephalosporin
WO2004009608A3 (en) Novel amorphous 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin a, process for preparing the same, and use thereof
EP1598356A4 (en) PROCESS FOR THE PREPARATION OF IRINOTECANHYDROCHLORIDE POLYMORPHES
NO20054911L (no) Fremgangsmate for fremstilling av et polymorft frosiglitazonmaleat
EA200600138A1 (ru) Способ получения кристаллического полиморфа ингибитора агрегации тромбоцитов
WO2008006720A3 (en) Crystalline nemorubicin hydrochloride
NO20055495L (no) 4-(4-trans-hydroksysykloheksyl)amino-2-fenyl-7H-pyrrolo[2,3-d]-pyrimidinhydrogenmesylat og dets polymorfe former
AR064728A1 (es) Formas amorfas y cristalinas de rimonabant, procesos para su preparacion y composiciones farmaceuticas que las contienen.
WO2004069790A3 (en) Crystalline modifications of triazinylaminostilbenes

Legal Events

Date Code Title Description
FG4A Patent for invention issued
FG4A Patent for invention issued
TC4A Change of name of proprietor (patent for invention)

Owner name: ALFASIGMA S.P.A., IT VIALE SARCA N.223, MILANO (MI

Free format text: PREVIOUS NAME OF PROPRIETOR: ALFA WASSERMANN S.P.A., IT VIA ENRICO FERMI, 1, I-65020 ALANNO (PE), ITALIA